ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Chimeric Antigen Receptor T-cells

Also written as “Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103”, “CAR T cells” and “CAR-T cells”.

Its studies are mostly in Glioma · Lymphoma, Non-Hodgkin · Colorectal Neoplasms · Leukemia, Myeloid, Acute · Carcinoma, Hepatocellular, led by 7 companies.

Drug pageChimeric Antigen Receptor T-cells: every studyMany companies study it; this page follows only the 8 they lead. All 68 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jun 15, 20248 company-led studies, 4 open or runningNext primary completion: May 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tcelltechits history only21 open or runningphase 1since Jun 15, 2024Jun 15, 2024none ahead
AGC Biologicsits history only10 open or runningphase 2since Aug 5, 2019Aug 5, 2019none ahead
Chongqing Precision Biotech11 open or runningphase 1since Jun 12, 2022Jun 12, 2022none ahead
Imunopharm Technologyits history only10 open or runningphase 1since Jan 27, 2021Jan 27, 2021none ahead
Shanghai Cell Therapy Groupits history only11 open or runningphase 1since Oct 11, 2021Oct 11, 2021none ahead
Shanghai GeneChemits history only10 open or runningphase 2since Nov 6, 2016Nov 6, 2016none ahead
Suzhou Immunofoco Biotechnologyits history only11 open or runningphase 3since Jul 17, 2025Jul 17, 2025May 31, 2027phase 3 · NCT07103668

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chongqing Precision Biotech only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2022First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05420493 · 54 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Chongqing Precision Biotech leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05420493Lymphoma, Non-Hodgkin · China1RecruitingSep 30, 202454

How it is read

Names in the registry

  • “Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103”, 2 entries
  • “CAR T cells”, 2 entries
  • “CAR-T cells”, 2 entries
  • “MLM-CAR44.1 T-cells at day 0 Single intravenous infusion”, 1 entry
  • “CAR-T cell”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.